gabexate has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daniluk, J | 1 |
| Liu, Y | 1 |
| Deng, D | 1 |
| Chu, J | 1 |
| Huang, H | 1 |
| Gaiser, S | 1 |
| Cruz-Monserrate, Z | 1 |
| Wang, H | 1 |
| Ji, B | 1 |
| Logsdon, CD | 1 |
1 other study available for gabexate and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Ceruletide; Cyclooxygenase 2 | 2012 |